Nephrotoxicity of high and conventional dosing regimens of colistin: A randomized clinical trial

Iranian Journal of Pharmaceutical Research

Volumn 16, Issue 2, 2017, Pages 778-787

  Javan, Atefeh Ordooei ^a   Shokouhi, Shervin ^b   Sahraei, Zahra ^a   Salamzadeh, Jamshid ^a   Armaki, Saeed Azad ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Khatam Hospital   (Iran)

Author keywords

Colistin; Conventional dose; Cystatin C; High dose; Nephrotoxicity

Indexed keywords

COLISTIN; CYSTATIN C;

ACINETOBACTER BAUMANNII; ACUTE KIDNEY FAILURE; ADULT; APACHE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EXPOSURE; DRUG MEGADOSE; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; KIDNEY FAILURE; KLEBSIELLA PNEUMONIAE; LUNG INFECTION; MALE; MIDDLE AGED; NEPHROTOXICITY; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

EID: 85021312970     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Falagas ME, Kasiakou SK and Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clinical. infectious. diseases. (2005) 40: 1333-41.
2. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR and Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis.(2006) 6: 589-601.
3. Nation RL and Li J. Colistin in the 21st century. Curr. Opin. Infect. Dis.(2009) 22: 535.
4. Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A, Forrest A, Bulitta JB and Tsuji BT. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics and dosing. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. (2010) 30: 1279-91.
5. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M and Regazzi M. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. CHEST J. (2010) 138: 1333-9.
6. Luque S, Grau S, Valle M, Sorlí L, Horcajada JP, Segura C and Álvarez-Lerma F. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant< i Acinetobacter baumannii. Int. J. Antimicrob. Agents. (2013) 42: 178-81.
7. Plachouras D, Karvanen M, Friberg L, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F and Armaganidis A. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.Antimicrob. Agents Chemother. (2009) 53: 3430-6.
8. Cheng C-Y, Sheng W-H, Wang J-T, Chen Y-C and Chang S-C. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.Int. J. Antimicrob. Agents (2010) 35: 297-300.
9. Michalopoulos AS and Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients.Ann. Intensive Care. (2011) 1: 1-6.
10. Roberts JA and Lipman J. Editorial commentary: closing the loop—a colistin clinical study to confirm dosing recommendations from PK/PD modeling. Clinical infectious diseases. (2012) 54: 1727-9.
11. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F and Brienza N. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.Clin. Infect. Dis. (2012) 54: 1720-6.
12. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ and Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation.Int. J. Antimicrob. Agents. (2005) 26: 504-7.
13. Falagas ME and Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies.Crit. Care. (2006) 10: R27.
14. Mendes CAC and Burdmann EA. Polymyxins: review with emphasis on nephrotoxicity.Revista da Associação Médica Brasileira. (2009) 55: 752-9.
15. Spapen H, Jacobs R, Van Gorp V, Troubleyn J and Honoré PM. Renal and neurological side effects of colistin in critically ill patients.Ann. Intensive Care. (2011) 1: 1-7.
16. Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD and Kalil A. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression.Clin. Infect. Dis. (2012) 54: 670-80.
17. Han WK and Bonventre JV. Biologic markers for the early detection of acute kidney injury.Curr. Opin. Crit. Care. (2004) 10: 476-82.
18. Soni SS, Ronco C, Katz N and Cruz DN. Early diagnosis of acute kidney injury: the promise of novel biomarkers.Blood Purif.(2009) 28: 165-74.
19. Garonzik S, Li J, Thamlikitkul V, Paterson D, Shoham S, Jacob J, Silveira F, Forrest A and Nation R. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.Antimicrob. Agents Chemother. (2011) 55: 3284-94.
20. Gurjar M. Colistin for lung infection: an update.J. Intensive Care (2015) 3: 1.
21. Ko H, Jeon M, Choo E, Lee E, Kim T, Jun J-B and Gil H-W. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clinical Practice. (2010) 117: c284-c8.
22. DeRyke CA, Crawford AJ, Uddin N and Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob. Agents Chemother. (2010) 54: 4503-5.
23. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P and Kaye KS. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system.Clin. Infect. Dis.(2011) 53: 879-84.
24. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL and Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int. J. Antimicrob. Agents. (2014) 43: 349-52.
25. Coca S, Yalavarthy R, Concato J and Parikh C. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review.Kidney Int. (2008) 73: 1008-16.
26. Herget-Rosenthal S, Marggraf G, Hüsing J, Göring F, Pietruck F, Janssen O, Philipp T and Kribben A. Early detection of acute renal failure by serum cystatin C.Kidney Int.(2004) 66: 1115-22.